NIMML
  • Menu
  • Go
  • About
  • Team
  • Research
  • Modeling
  • Clinical
  • Projects
  • News
  • Publications
  • Careers
  • Home people

Andrew Leber

Biography

Dr. Leber is a former PhD student in the NIMML, studying Genomics, Bioinformatics, and Computational Biology with a B.S. in biomedical engineering from PSU. Dr. Andrew Leber contributes deep knowledge of immunology, advanced computational modeling, data analytics, AI, and drug development to Landos Biopharma. As the Scientific Director, he is responsible for assessing the therapeutic potential of lead immunoregulatory targets in autoimmune diseases. Dr. Leber’s expertise in immunometabolism helped Landos advance its first-in-class asset for IBD, BT-11, into clinical development.

Contact

  • Phone: 540-231-8140
  • Email: andrew@nimml.org
  • Contact
  • Education
  • News & Events
  • Publications

© 2000 - 2025 NIMML Institute


  • Clinical
    • Clinical Development (Phase I-IV)
  • Pig Models
    • Neonatal pig model
    • Inflammatory bowel disease
    • Novel Pig Model of H. pylori
  • Media & Press Kit
    • Mission, Vision, Values
    • History
    • Quick Facts
    • Strategic Initiatives
  • ENISI Helicobacter Pylori Model
    • Sensitivity Analysis
    • Cell Movement Modeling
  • CDiff Computational Model Archive
    • Mucosal Immune Responses
    • PPAR γ and miRNA
  • EAEC Computational Model
    • Mucosal Immune Responses
    • T Cell Response
    • Epithelial Cell Responses
  • Macrophage Computational Model Archive
    • April 2012
    • Jan 2012
    • Oct 2011
  • COPASI Helicobacter Pylori Computational Model Archive
    • May 2012
    • April 2012
    • Jan 2012
    • Sep 2011
  • CD4+ T Cell Model Archive
    • Feb 2014
    • October 2012
    • August 2012
    • April 2012
    • Jan 2012
    • Sep 2011
    • June 2011
    • March 2011
  • Immunology
    • Helicobacter pylori
    • CD4+ T cell differentiation
    • Human Studies
    • Enteroaggregative E. coli
  • Animal Models
    • Type 2 Diabetes
    • Clostridium dificile infection
    • Influenza
    • Inflammatory bowel disease
    • Helicobacter pylori
    • Pig Models
    • Murine Models
  • Infectious Diseases
    • Helicobacter pylori
    • Clostridium difficile
    • Enteroaggregative E. coli
  • Immune Mediated Diseases
    • Novel IBD Interventions
  • Nutritional Immunology
    • Novel IBD Interventions
    • Phytochemicals
    • Dietary Lipids
    • Prebiotics and Probiotics
  • Drug Development
    • Host-targeted Therapeutics
    • Translational Medicine
  • Data
    • Modeling NLRX1 response to H.pylori
    • Modeling Clostridium difficile Immune Response
    • EAEC Zinc Deficiency
    • IL-21 in the Gastric Mucosa
    • Novel Pig Model
    • CD4+ T Cells
    • Modeling H. pylori Immune Response
    • Clostridium difficile
    • Enteroaggregative Escherichia coli
    • ENISI V0.9 in silico experiments
  • Computational Models
    • Inflammatory bowel disease
    • CD4+ T Cell Model
    • Host Responses to H. pylori
    • Host Responses to EAEC
    • Host Responses to C. difficile
    • Macrophages
  • Tools
    • CMS
    • CellDesigner
    • ENISI Suite
    • COPASI Suite
    • Galaxy
    • LabKey
    • RedCap
    • Intranet
    • CellPublisher
  • Projects
    • Alternate Preclinical Models Of Enteric Infection
    • Modeling Infectious Disease Kinetics (MIDK-cWMD)
  • Immunoinformatics
    • Computational Modeling
    • High Performance Computing
    • Transcriptomics
  • NIMML POLICIES
    • FCOI